• About
• Links
• Contact
• Sitemap
• 

The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global autoimmune diseases therapeutics market. The report analyzes the markets for autoimmune disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

Scope

The scope of this report includes:

Annualized market data for the autoimmune diseases therapeutics market from 2000 to 2008, forecast forward to 2015

Analysis of the leading therapeutic segments including rheumatoid arthritis, multiple sclerosis, systemic lupus, erythematosus, crohn’s disease and ulcerative colitis

Analysis of the autoimmune diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

Market characterization of the autoimmune diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns

Key drivers and barriers that have a significant impact on the market

Coverage of pipeline molecules in various phases of drug development

Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Amgen Inc, AstraZeneca, Merck & Co, Pfizer Inc, Celgene Corporation, Bristol-Myers Squibb and Eli Lilly

Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global autoimmune diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align product portfolio to the markets with high growth potential

Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

Develop key strategic initiatives by understanding key focus areas of leading companies

Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction To the Global Autoimmune Disease Therapeutics Market

• 2.1 Introduction
• 2.2 Report Guidance

3 Global Autoimmune Disease Therapeutics Market: Market Characterization

• 3.1 Market Overview
• 3.2 Market Forecasts
• 3.3 Branded Versus Generics
• 3.4 Market Share by Disease Sectors
• 3.5 Average Cost of Therapy
• 3.6 Volume
• 3.7 Usage Patterns
  • 3.7.1 Diseased Population
  • 3.7.2 Treatment Seeking Population
  • 3.7.3 Diagnosis Population
  • 3.7.4 Prescription Population
  • 3.7.5 Therapeutics Usage Patterns
• 3.8 Geographical Distribution
• 3.9 Drivers and Restraints
  • 3.9.1 Market Drivers
  • 3.9.2 Market Restraints
• 3.10 Unmet Needs
• 3.11 Key Market Trends
  • 3.11.1 Growing Patient Population and Medical Proclivity for Long Term Treatments
  • 3.11.2 High levels of Unmet Need
  • 3.11.3 Increasing Acceptance of Biologics for Autoimmune Disease Treatment
  • 3.11.4 Increase in Drug Label Extension Over the Forecast Period
  • 3.11.5 Increase in Strategic Consolidation Within the Autoimmune Disease Therapeutics Market

4 Global Rheumatoid Arthritis Therapeutics Market

• 4.1 Market Overview
• 4.2 Market Forecasts
• 4.3 Average Cost of Therapy
• 4.4 Volume
• 4.5 Usage Patterns
  • 4.5.1 Diseased Population
  • 4.5.2 Treatment Seeking Population
  • 4.5.3 Diagnosis Population
  • 4.5.4 Prescription Population
  • 4.5.5 Therapeutic Usage Patterns
• 4.6 Product Analysis
  • 4.6.1 Orencia
  • 4.6.2 Voltaren/Cataflam
  • 4.6.3 Enbrel
  • 4.6.4 Remicade
  • 4.6.5 Humira
  • 4.6.6 Rituxan
  • 4.6.7 Prograf
  • 4.6.8 Rheumatrex
  • 4.6.9 Celebrex
  • 4.6.10 Arava
• 4.7 Drug Pipeline Analysis

5 Global Systemic Lupus Erythematosus Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Forecasts
• 5.3 Average Cost of Therapy
• 5.4 Volume
• 5.5 Usage Patterns
  • 5.5.1 Diseased Population
  • 5.5.2 Treatment Seeking Population
  • 5.5.3 Diagnosis Population
  • 5.5.4 Prescription Population
  • 5.5.5 Therapeutic Usage Patterns
• 5.6 Product Analysis
  • 5.6.1 CellCept
  • 5.6.2 Medrol/Depo-Medrol
  • 5.6.3 Plaquenil
  • 5.6.4 Imuran
  • 5.6.5 Azasan
  • 5.6.6 Cyclophosphamide
  • 5.6.7 Rituximab
• 5.7 Drug Pipeline Analysis

6 Global Multiple Sclerosis Therapeutics Market

• 6.1 Market Overview
• 6.2 Market Forecasts
• 6.3 Average Cost of Therapy
• 6.4 Volume
• 6.5 Usage Patterns
  • 6.5.1 Diseased Population
  • 6.5.2 Treatment Seeking Population
  • 6.5.3 Diagnosis Population
  • 6.5.4 Prescription Population
  • 6.5.5 Therapeutic Usage Patterns
• 6.6 Product Analysis
  • 6.6.1 Avonex
  • 6.6.2 Acthar
  • 6.6.3 Betaferon/Betaseron
  • 6.6.4 Copaxone
  • 6.6.5 Rebif
  • 6.6.6 Tysabri
• 6.7 Drug Pipeline Analysis

7 Global Psoriasis Therapeutics Market

• 7.1 Market Overview
• 7.2 Market Forecasts
• 7.3 Average Cost of Therapy
• 7.4 Volume
• 7.5 Usage Patterns
  • 7.5.1 Diseased Population
  • 7.5.2 Treatment Seeking Population
  • 7.5.3 Diagnosis Population
  • 7.5.4 Prescription Population
  • 7.5.5 Therapeutic Usage Patterns
• 7.6 Product Analysis
  • 7.6.1 Amevive
  • 7.6.2 Dovonex
  • 7.6.3 Enbrel
  • 7.6.4 Fumaderm
  • 7.6.5 Humira
  • 7.6.6 Neoral
  • 7.6.7 Raptiva
  • 7.6.8 Remicade
  • 7.6.9 Tazorac
• 7.7 Drug Pipeline Analysis

8 Global Crohn’s Disease Therapeutics Market

• 8.1 Market Overview
• 8.2 Market Forecasts
• 8.3 Average Cost of Therapy
• 8.4 Volume
• 8.5 Usage Patterns
  • 8.5.1 Diseased Population
  • 8.5.2 Treatment Seeking Population
  • 8.5.3 Diagnosis Population
  • 8.5.4 Prescription Population
  • 8.5.5 Therapeutics Usage Patterns
• 8.6 Product Analysis
  • 8.6.1 Asacol
  • 8.6.2 Cimzia
  • 8.6.3 Entocort EC
  • 8.6.4 Humira
  • 8.6.5 Remicade
• 8.7 Drug Pipeline Analysis

9 Global Ulcerative Colitis Therapeutics Market

• 9.1 Market Overview
• 9.2 Market Forecasts
• 9.3 Average Cost of Therapy
• 9.4 Volume
• 9.5 Usage Patterns
  • 9.5.1 Diseased Population
  • 9.5.2 Treatment Seeking Population
  • 9.5.3 Diagnosis Population
  • 9.5.4 Prescription Population
  • 9.5.5 Therapeutic Usage Patterns
• 9.6 Product Analysis
  • 9.6.1 Asacol
  • 9.6.2 Apriso
• 9.7 Drug Pipeline Analysis

10 Global Autoimmune Disease Therapeutics Market: The US Market

• 10.1 Market Overview
• 10.2 Market Forecasts
• 10.3 Average Cost of Therapy
• 10.4 Volume
• 10.5 Usage Patterns
  • 10.5.1 Diseased Population
  • 10.5.2 Treatment Seeking Population
  • 10.5.3 Diagnosis Population
  • 10.5.4 Prescription Population
  • 10.5.5 Therapeutic Usage Patterns

11 Global Autoimmune Disease Therapeutics Market: The European Market

• 11.1 Market Overview
• 11.2 Market Forecasts
• 11.3 Average Cost of Therapy
• 11.4 Volume
• 11.5 Usage Patterns
  • 11.5.1 Diseased Population
  • 11.5.2 Treatment Seeking Population
  • 11.5.3 Diagnosis Population
  • 11.5.4 Prescription Population
  • 11.5.5 Therapeutic Usage Patterns

12 Global Autoimmune Disease Therapeutics Market: The Japanese Market

• 12.1 Market Overview
• 12.2 Market Forecasts
• 12.3 Average Cost of Therapy
• 12.4 Volume
• 12.5 Usage Patterns
  • 12.5.1 Diseased Population
  • 12.5.2 Treatment Seeking Population
  • 12.5.3 Diagnosis Population
  • 12.5.4 Prescription Population
  • 12.5.5 Therapeutic Usage Patterns

13 Global Autoimmune Disease Therapeutics Market: Competitive Landscape

• 13.1 Overview
• 13.2 Competitive Profiling
  • 13.2.1 Amgen
  • 13.2.2 Bristol-Myers Squibb
  • 13.2.3 Novartis
  • 13.2.4 Pfizer
  • 13.2.5 Bayer AG
  • 13.2.6 Biogen Idec.
  • 13.2.7 Roche
  • 13.2.8 Sanofi-aventis
  • 13.2.9 Johnson & Johnson
  • 13.2.10 Shire Pharmaceuticals
  • 13.2.11 UCB Pharma
  • 13.2.12 Salix Pharmaceuticals
  • 13.2.13 Abbott Pharmaceuticals
  • 13.2.14 Takeda Pharmaceutical
  • 13.2.15 Teva Pharmaceuticals
  • 13.2.16 Santen Pharma
  • 13.2.17 Warner Chilcott
  • 13.2.18 Roxane labs
  • 13.2.19 Questcor Pharmaceutical
  • 13.2.20 Procter & Gamble Pharmaceuticals
  • 13.2.21 Merck Serono
  • 13.2.22 Forest Laboratories
  • 13.2.23 Allergan Pharmaceuticals
  • 13.2.24 Astellas Pharma Inc.
  • 13.2.25 King Pharmaceuticals
  • 13.2.26 Prometheus Labs

14 Global Autoimmune Disease Therapeutics Market: Strategic Consolidations

• 14.1 Mergers and Acquisitions (M&A)
  • 14.1.1 Cephalon, Inc. Acquired Arana Therapeutics Limited
  • 14.1.2 Johnson & Johnson Acquired Elan Corporation plc
  • 14.1.3 Bayer Healthcare acquired Genzyme Corp.
  • 14.1.4 Paladin Labs Inc. acquired ViRexx Medical Corp.
• 14.2 Licensing Agreements
  • 14.2.1 Overview
  • 14.2.2 Discovery and Preclinical
  • 14.2.3 Phase I
  • 14.2.4 Phase II
  • 14.2.5 Phase III
  • 14.2.6 Approved

15 Appendix

• 15.1 Market Definitions
• 15.2 Abbreviations
• 15.3 Research Methodology
  • 15.3.1 Coverage
  • 15.3.2 Secondary Research
  • 15.3.3 Primary Research
  • 15.3.4 Forecasts
  • 15.3.5 Expert Panel Validation
• 15.4 Contact Us
• 15.5 Disclaimer

1.1 List of Tables

• Table 1: Autoimmune Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008
• Table 2: Autoimmune Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015
• Table 3: Autoimmune Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008
• Table 4: Autoimmune Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
• Table 5: Autoimmune Disease Therapeutics Market, Global, Volume, 2000-2008
• Table 6: Autoimmune Disease Therapeutics Market, Global, Volume, 2008-2015
• Table 7: Autoimmune Disease Therapeutics Market, Global, Diseased Population, 2000-2008
• Table 8: Autoimmune Disease Therapeutics Market, Global, Diseased Population, 2008-2015
• Table 9: Autoimmune Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2008
• Table 10: Autoimmune Disease Therapeutics Market, Global, Treatment Seeking Population, 2008-2015
• Table 11: Autoimmune Disease Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Table 12: Autoimmune Disease Therapeutics Market, Global, Diagnosis Population, 2008-2015
• Table 13: Autoimmune Disease Therapeutics Market, Global, Prescription Population, 2000-2008
• Table 14: Autoimmune Disease Therapeutics Market, Global, Prescription Population, 2008-2015
• Table 15: Autoimmune Disease Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008
• Table 16: Autoimmune Disease Therapeutics Market, Global, Therapeutic Usage Patterns, 2008-2015
• Table 17: Autoimmune Disease Therapeutics Market, Global, Market Drivers, 2008
• Table 18: Autoimmune Disease Therapeutics Market, Global, Market Restraints, 2008
• Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008
• Table 20: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($mn), 2008-2015
• Table 21: Rheumatoid Arthritis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008
• Table 22: Rheumatoid Arthritis Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
• Table 23: Rheumatoid Arthritis Therapeutics Markets, Global, Volume, 2000-2008
• Table 24: Rheumatoid Arthritis Therapeutics Market, Global, Volume, 2008-2015
• Table 25: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population, 2000-2008
• Table 26: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population, 2008-2015
• Table 27: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population, 2000-2008
• Table 28: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population, 2008-2015
• Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population, 2008-2015
• Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population, 2000-2008
• Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population, 2008-2015
• Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008
• Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Therapeutic Usage Patterns, 2008-2015
• Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
• Table 36: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008
• Table 37: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015
• Table 38: Systemic Lupus Erythematosus Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008
• Table 39: Systemic Lupus Erythematosus Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
• Table 40: Systemic Lupus Erythematosus Therapeutics Market, Global, Volume, 2000-2008
• Table 41: Systemic Lupus Erythematosus Therapeutics Market, Global, Volume, 2008-2015
• Table 42: Systemic Lupus Erythematosus Therapeutics Market, Global, Diseased Population, 2000-2008
• Table 43: Systemic Lupus Erythematosus Therapeutics Market, Global, Diseased Population, 2008-2015
• Table 44: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Seeking Population, 2000-2008
• Table 45: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Seeking Population, 2008-2015
• Table 46: Systemic Lupus Erythematosus Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Table 47: Systemic Lupus Erythematosus Therapeutics Market, Global, Diagnosis Population, 2008-2015
• Table 48: Systemic Lupus Erythematosus Therapeutics Market, Global, Prescription Population, 2000-2008
• Table 49: Systemic Lupus Erythematosus Therapeutics Market, Global, Prescription Population, 2008-2015
• Table 50: Systemic Lupus Erythematosus Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008
• Table 51: Systemic Lupus Erythematosus Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015
• Table 52: Rheumatoid Arthritis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
• Table 53: Multiple Sclerosis Therapeutics Market, Global, Revenue Revenue Forecasts ($mn), 2000-2008
• Table 54: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015
• Table 55: Multiple Sclerosis Therapeutics Market, Global, Average Cost of Therapy, 2000-2008
• Table 56: Multiple Sclerosis Therapeutics Market, Global, Average Cost of Therapy, 2008-2015
• Table 57: Multiple Sclerosis Therapeutics Market, Global, Volume, 2000-2008
• Table 58: Multiple Sclerosis Therapeutics Market, Global, Volume, 2008-2015
• Table 59: Multiple Sclerosis Therapeutics Market, Global, Diseased Population, 2000-2008
• Table 60: Multiple Sclerosis Therapeutics Market, Global, Diseased Population, 2008-2015
• Table 61: Multiple Sclerosis Therapeutics Market, Global, Volume, 2000-2008
• Table 62: Multiple Sclerosis Therapeutics Market, Global, Volume, 2008-2015
• Table 63: Multiple Sclerosis Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Table 64: Multiple Sclerosis Therapeutics Market, Global, Diagnosis Population, 2008-2015
• Table 65: Multiple Sclerosis Therapeutics Market, Global, Prescription Population, 2000-2008
• Table 66: Multiple Sclerosis Therapeutics Market, Global, Prescription Population, 2008-2015
• Table 67: Multiple Sclerosis Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2008
• Table 68: Multiple Sclerosis Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015
• Table 69: Multiple Sclerosis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
• Table 70: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008
• Table 71: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015
• Table 72: Psoriasis Therapeutics Market, Global, Average Cost of Therapy, 2000-2008
• Table 73: Psoriasis Therapeutics Market, Global, Average Cost of Therapy, 2008-2015
• Table 74: Psoriasis Therapeutics Market, Global, Volume, 2000-2008
• Table 75: Psoriasis Therapeutics Market, Global, Volume, 2008-2015
• Table 76: Psoriasis Therapeutics Market, Global, Diseased Population, 2000-2008
• Table 77: Psoriasis Therapeutics Market, Global, Diseased Population, 2008-2015
• Table 78: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2000-2008
• Table 79: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2008-2015
• Table 80: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Table 81: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2008-2015
• Table 82: Psoriasis Therapeutics Market, Global, Prescription Population, 2000-2008
• Table 83: Psoriasis Therapeutics Market, Global, Prescription Population, 2008-2015
• Table 84: Psoriasis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008
• Table 85: Psoriasis Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015
• Table 86: Psoriasis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
• Table 87: Crohn’s Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008
• Table 88: Crohn’s Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015
• Table 89: Crohn’s Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008
• Table 90: Crohn’s Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
• Table 91: Crohn’s Disease Therapeutics Market, Global, Volume, 2000-2008
• Table 92: Crohn’s Disease Therapeutics Market, Global, Volume, 2008-2015
• Table 93: Crohn’s Disease Therapeutics Market, Global, Diseased Population, 2000-2008
• Table 94: Crohn’s Disease Therapeutics Market, Global, Diseased Population, 2008-2015
• Table 95: Crohn’s Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2008
• Table 96: Crohn’s Disease Therapeutics Market, Global, Treatment Seeking Population, 2008-2015
• Table 97: Crohn’s Disease Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Table 98: Crohn’s Disease Therapeutics Market, Global, Diagnosis Population, 2008-2015
• Table 99: Crohn’s Disease Therapeutics Market, Global, Prescription Population, 2000-2008
• Table 100: Crohn’s Disease Therapeutics Market, Global, Prescription Population, 2008-2015
• Table 101:Crohn’s Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2008
• Table 102:Crohn’s Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015
• Table 103:Crohn’s Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
• Table 104:Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008
• Table 105:Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015
• Table 106:Ulcerative Colitis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008
• Table 107: Ulcerative Colitis Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
• Table 108:Ulcerative Colitis Therapeutics Market, Global, Volume, 2000-2008
• Table 109: Ulcerative Colitis Therapeutics Market, Global, Volume, 2008-2015
• Table 110:Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2000-2008
• Table 111:Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2008-2015
• Table 112:Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2000-2008
• Table 113:Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2008-2015
• Table 114:Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Table 115:Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2008-2015
• Table 116:Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2000-2008
• Table 117:Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2008-2015
• Table 118:Ulcerative Colitis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008
• Table 119:Ulcerative Colitis Therapeutics Market, Global, Therapeutic Usage Patterns, Global, 2008-2015
• Table 120:Ulcerative Colitis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
• Table 121:Autoimmune Disease Therapeutics Market, US, Revenue Forecasts ($mn), 2000-2008
• Table 122:Autoimmune Disease Therapeutics Market, US, Revenue Forecasts ($mn), 2008-2015
• Table 123:Autoimmune Disease Therapeutics Market, US, Average Cost of Therapy ($), 2000-2008
• Table 124:Autoimmune Disease Therapeutics Market, US, Average Cost of Therapy ($), 2008-2015
• Table 125: Autoimmune Disease Therapeutics Market, US, Volume, 2000-2008
• Table 126: Autoimmune Disease Therapeutics Market, US, Volume, 2008-2015
• Table 127: Autoimmune Disease Therapeutics Market, US, Diseased Population, 2000-2008
• Table 128: Autoimmune Disease Therapeutics Market, US, Diseased Population, 2008-2015
• Table 129: Autoimmune Disease Therapeutics Market, US, Treatment Seeking Population, 2000-2008
• Table 130: Autoimmune Disease Therapeutics Market, US, Treatment Seeking Population, 2008-2015
• Table 131: Autoimmune Disease Therapeutics Market, US, Diagnosis Population, 2000-2008
• Table 132: Autoimmune Disease Therapeutics Market, US, Diagnosis Population, 2008-2015
• Table 133: Autoimmune Disease Therapeutics Market, US, Prescription Population, 2000-2008
• Table 134: Autoimmune Disease Therapeutics Market, US, Prescription Population, 2008-2015
• Table 135: Autoimmune Disease Therapeutics Market, US, Therapeutics Usage Patterns, 2000-2008
• Table 136: Autoimmune Disease Therapeutics Market, US, Therapeutics Usage Patterns, 2008-2015
• Table 137: Autoimmune Disease Therapeutics Market, Europe, Revenue Forecasts ($mn), 2000-2008
• Table 138: Autoimmune Disease Therapeutics Market, Europe, Revenue Forecasts ($mn), 2008-2015
• Table 139: Autoimmune Disease Therapeutics Market, Europe, Average Cost of Therapy ($), 2000-2008
• Table 140: Autoimmune Disease Therapeutics Market, Europe, Average Cost of Therapy ($), 2008-2015
• Table 141: Autoimmune Disease Therapeutics Market, Europe, Volume, 2000-2008
• Table 142: Autoimmune Disease Therapeutics Market, Europe, Volume, 2008-2015
• Table 143: Autoimmune Disease Therapeutics Market, Europe, Diseased Population, 2000-2008
• Table 144: Autoimmune Disease Therapeutics Market, Europe, Diseased Population, 2008-2015
• Table 145: Autoimmune Disease Therapeutics Market, Europe, Treatment Seeking Population, 2000-2008
• Table 146: Autoimmune Disease Therapeutics Market, Europe, Treatment Seeking Population, 2008-2015
• Table 147: Autoimmune Disease Therapeutics Market, Europe, Diagnosis Population, 2000-2008
• Table 148: Autoimmune Disease Therapeutics Market, Europe, Diagnosis Population, 2008-2015
• Table 149: Autoimmune Disease Therapeutics Market, Europe, Prescription Population, 2000-2008
• Table 150: Autoimmune Disease Therapeutics Market, Europe, Prescription Population, 2008-2015
• Table 151: Autoimmune Disease Therapeutics Market, Europe, Therapeutic Usage Patterns, 2000-2008
• Table 152: Autoimmune Disease Therapeutics Market, Europe, Therapeutic Usage Patterns, 2008-2015
• Table 153: Autoimmune Disease Therapeutics Market, Japan, Revenue Forecasts ($mn), 2000-2008
• Table 154: Autoimmune Disease Therapeutics Market, Japan, Revenue Forecasts ($mn), 2000-2015
• Table 155: Autoimmune Disease Therapeutics Market, Japan, Average Cost of Therapy, 2000-2008
• Table 156: Autoimmune Disease Therapeutics Market, Japan, Average Cost of Therapy, 2008-2015
• Table 157: Autoimmune Disease Therapeutics Market, Japan, Volume, 2000-2008
• Table 158: Autoimmune Disease Therapeutics Market, Japan, Volume, 2008-2015
• Table 159: Autoimmune Disease Therapeutics Market, Japan, Diseased Population, 2000-2008
• Table 160: Autoimmune Disease Therapeutics Market, Japan, Diseased Population, 2008-2015
• Table 161: Autoimmune Disease Therapeutics Market, Japan, Treatment Seeking Population, 2000-2008
• Table 162: Autoimmune Disease Therapeutics Market, Japan, Treatment Seeking Population, 2008-2015
• Table 163: Autoimmune Disease Therapeutics Market, Japan, Diagnosis Population, 2000-2008
• Table 164: Autoimmune Disease Therapeutics Market, Japan, Diagnosis Population, 2008-2015
• Table 165: Autoimmune Disease Therapeutics Market, Japan, Prescription Population, 2000-2008
• Table 166: Autoimmune Disease Therapeutics Market, Japan, Prescription Population, 2008-2015
• Table 167:Autoimmune Disease Therapeutics Market, Japan, Therapeutics Usage Patterns, 2000-2008
• Table 168:Autoimmune Disease Therapeutics Market, Japan, Therapeutics Usage Patterns, 2008-2015
• Table 169: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Discovery and Preclinical Stages, 2008
• Table 170: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I Stage, 2008
• Table 171: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stage, 2008
• Table 172: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stage, 2008
• Table 173: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Approved Stage, 2008

1.2 List of Figures

• Figure 1: Global Autoimmune Disease Therapeutics Market, Global Percentage Incidence of Autoimmune Diseases by Sex, 2008
• Figure 2: Autoimmune Disease Therapeutics Market, Global, Major Factors Influencing the Market, 2008
• Figure 3: Autoimmune Disease Therapeutics Market, Global, Key Geographical Trends, 2008
• Figure 4: Autoimmune Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015
• Figure 5: Autoimmune Disease Therapeutics Market, Global, Revenue Split ($bn), 2000-2015
• Figure 6: Autoimmune Therapeutics Market, Global, Market Share of Disease Sectors, 2008
• Figure 7: Autoimmune Disease Therapeutics Market, Global, Comparative Assessment of Key Autoimmune Disease Sectors, 2008
• Figure 8: Autoimmune Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
• Figure 9: Autoimmune Disease Therapeutics Market, Global, Volume, 2000-2015
• Figure 10: Autoimmune Disease Therapeutics Market, Global, Diseased Population, 2000-2015
• Figure 11: Autoimmune Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2015
• Figure 12: Autoimmune Disease Therapeutics Market, Global, Diagnosis Population, 2000-2015
• Figure 13: Autoimmune Disease Therapeutics Market, Global, Prescription Population, 2000-2015
• Figure 14: Autoimmune Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015
• Figure 15: Autoimmune Disease Therapeutics Market, Global, Geographical Distribution of Revenues ($mn), 2000-2015
• Figure 16: Autoimmune Disease Therapeutics Market, Global, Market Indicators, 2008
• Figure 17: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Rheumatoid Arthritis Therapeutics, 2008
• Figure 18: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Rheumatoid Arthritis Therapeutics, 2008
• Figure 19: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for SLE Therapeutics, 2008
• Figure 20: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Ulcerative Colitis Therapeutics, 2008
• Figure 21: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Crohn’s Disease Therapeutics, 2008
• Figure 22: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Multiple Sclerosis Therapeutics, 2008
• Figure 23: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Psoriasis Therapeutics, 2008
• Figure 24: Autoimmune Disease Therapeutics Market, Global, Correlation Between Growth in Prescription Population and Market Revenues, 2000-2015
• Figure 25: Autoimmune Disease Therapeutics Market, Global, Comparative Analysis of Growth in Biologics Versus Chemotherapy, 2000-2015
• Figure 26: Autoimmune Disease Therapeutics Market, Global, Assessment of Growth in Drug Label Extensions, 2000-2015
• Figure 27: Autoimmune Disease Therapeutics Market, Global, Assessment of Growth in M&A and Licensing Agreements, 2008-2009
• Figure 28: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015
• Figure 29: Rheumatoid Arthritis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
• Figure 30: Rheumatoid Arthritis Therapeutics Market, Global, Volume, 2000-2015
• Figure 31: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population, 2000-2015
• Figure 32: Rheumatoid Arthritis Market, Global, Treatment Seeking Population, 2000-2015
• Figure 33: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population, 2000-2008
• Figure 34: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population, 2000-2015
• Figure 35: Rheumatoid Arthritis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2015
• Figure 36: Rheumatoid Arthritis Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008
• Figure 37: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts of Major Drugs, 2006-2008
• Figure 38: Rheumatoid Arthritis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008
• Figure 39: Rheumatoid Arthritis Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008
• Figure 40: Rheumatoid Arthritis Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008
• Figure 41: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015
• Figure 42: Systemic Lupus Erythematosus Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
• Figure 43: Systemic Lupus Erythematosus Therapeutics Market, Global, Volume, 2000-2015
• Figure 44: Systemic Lupus Erythematosus Therapeutics Market, Global, Diseased Population, 2000-2015
• Figure 45: Systemic Lupus Erythematosus Therapeutics Market, Global, the Treatment Seeking Population, 2000-2015
• Figure 46: Systemic Lupus Erythematosus Therapeutics Market, Global, Diagnosis Population, 2000-2015
• Figure 47: Systemic Lupus Erythematosus Therapeutics Market, Global, Prescription Population, 2000-2015
• Figure 48: Systemic Lupus Erythematosus Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015
• Figure 49: Systemic Lupus Erythematosus Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008
• Figure 50: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts of Major Drugs, 2006-2008
• Figure 51: Systemic Lupus Erythematosus Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008
• Figure 52: Systemic Lupus Erythematosus Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008
• Figure 53: Systemic Lupus Erythematosus Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008
• Figure 54: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015
• Figure 55: Multiple Sclerosis Therapeutics Market, Global, Average Cost of Therapy, 2000-2015
• Figure 56: Multiple Sclerosis Therapeutics Market, Global, Volume, 2000-2015
• Figure 57: Multiple Sclerosis Therapeutics Market, Global, Diseased Population, 2000-2015
• Figure 58: Multiple Sclerosis Therapeutics Market, Global, Treatment Seeking Population, 2000-2015
• Figure 59: Multiple Sclerosis Therapeutics Market, Global, Diagnosis Population, 2000-2015
• Figure 60: Multiple Sclerosis Therapeutics Market, Global, Prescription Population, 2000-2015
• Figure 61: Multiple Sclerosis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2015
• Figure 62: Multiple Sclerosis Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008
• Figure 63: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts of Major Drugs, 2006-2008
• Figure 64: Multiple Sclerosis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008
• Figure 65: Multiple Sclerosis Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008
• Figure 66: Multiple Sclerosis Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008
• Figure 67: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015
• Figure 68: Psoriasis Therapeutics Market, Global, Average Cost of Therapy, 2000-2015
• Figure 69: Psoriasis Therapeutics Market, Global, Volume, 2000-2015
• Figure 70: Psoriasis Therapeutics Market, Global, Diseased Population, 2000-2015
• Figure 71: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2000-2015
• Figure 72: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2000-2015
• Figure 73: Psoriasis Therapeutics Market, Global, Prescription Population, 2000-2015
• Figure 74: Psoriasis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2015
• Figure 75: Psoriasis Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008
• Figure 76: Psoriasis Therapeutics Market, Global, Revenue Major Drugs, 2006-2008
• Figure 77: Psoriasis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008
• Figure 78: Psoriasis Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008
• Figure 79: Psoriasis Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008
• Figure 80: Crohn’s Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015
• Figure 81: Crohn’s Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
• Figure 82: Crohn’s Disease Therapeutics Market, Global, Volume, 2000-2015
• Figure 83: Crohn’s Disease Therapeutics Market, Global, Disease Population, 2000-2015
• Figure 84: Crohn’s Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2015
• Figure 85: Crohn’s Disease Therapeutics Market, Global, Diagnosis Population, 2000-2015
• Figure 86: Crohn’s Disease Therapeutics Market, Global, Prescription Population, 2000-2015
• Figure 87: Crohn’s Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015
• Figure 88: Crohn’s Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008
• Figure 89: Crohn’s Disease Therapeutics Market, Global, Revenue Major Drugs, 2006-2008
• Figure 90: Crohn’s Disease Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008
• Figure 91: Crohn’s Disease Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008
• Figure 92: Crohn’s Disease Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008
• Figure 93: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015
• Figure 94: Ulcerative Colitis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
• Figure 95: Ulcerative Colitis Therapeutics Market, Global, Volume, 2000-2015
• Figure 96: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2000-2015
• Figure 97: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2000-2015
• Figure 98: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2000-2015
• Figure 99: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2000-2015
• Figure 100:Ulcerative Colitis Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015
• Figure 101:Ulcerative Colitis Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008
• Figure 102:Ulcerative Colitis Therapeutics Market, Global, Revenue Major Drugs, 2006-2008
• Figure 103:Ulcerative Colitis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008
• Figure 104:Ulcerative Colitis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008
• Figure 105:Ulcerative Colitis Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008
• Figure 106:Autoimmune Disease Therapeutics Market, US, Revenue Forecasts ($mn), 2000-2015
• Figure 107:Autoimmune Disease Therapeutics, US, Average Cost of Therapy ($), 2000-2015
• Figure 108: Autoimmune Disease Therapeutics Market, US, Volume, 2000-2015
• Figure 109: Autoimmune Disease Therapeutics Market, US, Diseased Population, 2000-2015
• Figure 110: Autoimmune Disease Therapeutics Market, US, Treatment Seeking Population, 2000-2015
• Figure 111: Autoimmune Disease Therapeutics Market, US, Diagnosis Population, 2000-2015
• Figure 112: Autoimmune Disease Therapeutics Market, US, Prescription Population, 2000-2015
• Figure 113: Autoimmune Disease Therapeutics Market, US, Therapeutics Usage Patterns, 2000-2015
• Figure 114: Autoimmune Disease Therapeutics Market, Europe, Revenue Forecasts, 2000-2015
• Figure 115: Autoimmune Disease Therapeutics Market, Europe, Average Cost of Therapy ($), 2000-2015
• Figure 116: Autoimmune Disease Therapeutics Market, Europe, Volume, 2000-2015
• Figure 117: Autoimmune Disease Therapeutics Market, Europe, Diseased Population, 2000-2008
• Figure 118: Autoimmune Disease Therapeutics Market, Europe, Treatment Seeking Population, 2000-2008
• Figure 119: Autoimmune Disease Therapeutics Market, Europe, Diagnosis Population, 2000-2015
• Figure 120: Autoimmune Disease Therapeutics Market, Europe, Prescription Population, 2000-2015
• Figure 121: Autoimmune Disease Therapeutics Market, Europe, Therapeutic Usage Patterns, 2000-2015
• Figure 122: Autoimmune Disease Therapeutics Market, Japan, Revenue Forecasts ($mn), 2000-2015
• Figure 123: Autoimmune Disease Therapeutics Market, Japan, Average Cost of Therapy ($), 2000-2015
• Figure 124: Autoimmune Disease Therapeutics Market, Japan, Volume, 2000-2015
• Figure 125: Autoimmune Disease Therapeutics Market, Japan, Diseased Population, 2000-2015
• Figure 126: Autoimmune Disease Therapeutics Market, Japan, Treatment Seeking Population, 2000-2015
• Figure 127: Autoimmune Disease Therapeutics Market, Japan, Diagnosis Population, 2000-2015, November 2009
• Figure 128: Autoimmune Disease Therapeutics Market, Japan, Prescription Population, 2000-2015
• Figure 129: Autoimmune Disease Therapeutics Market, Japan, Therapeutics Usage Patterns, 2000-2015
• Figure 130: Autoimmune Disease Therapeutics Market, Global, Competitive Analysis of Major Manufacturers with Respect to Revenues ($mn), 2006-2008
• Figure 131: Global Autoimmune Disease Therapeutics Market, Market Share of Top Manufacturers, 2008
• Figure 132: Global Autoimmune Disease Therapeutics Market, Competitive Analysis of Top 6 Manufacturers with Respect to Pipeline, Revenues and CAGR, 2008-2015
• Figure 133: Autoimmune Disease Therapeutics Market, Global, M&A Split by Phases of Development and Geography, 2008
• Figure 134: Autoimmune Disease Therapeutics Market, Global, M&A Split by Deal Type and Deal Value, 2008
• Figure 135: Autoimmune Disease Therapeutics Market, Global, M&A Split by Deal Type and Deal Value, 2008
• Figure 136: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements Split by Phases of Development and Geography, 2008
• Figure 137: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements Split by Disease Sectors and Deal Value, 2008
• Figure 138: Research Methodology
• Figure 139: Research Market Forecasting Model

Other users found this report page using the following search terms: rheumatoid arthritis multiple sclerosis systemic lupus erythematosus crohn ulcerative colitis ibd market autoimmune disease diseases therapeutics autoimmunediseasesmarketforecast pipeline deals futureofautoimmunetherapy entocort

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.